Navigation Links
Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
Date:5/23/2011

feels and conforms to the donor site. So far, results are good and look very promising."- Dr. Marcus Wong, Study Investigator, Consultant and Section Head, Plastic, Reconstructive and Aesthetic Surgery, Tan Tock Seng Hospital, Singapore.

TIGR® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. US FDA cleared TIGR® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR® Matrix Surgical Mesh throughout the United States, Canada, and Latin America.

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:  

Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.com
James Archetto: +1-781-577-2599 - jim.archetto@novusscientific.com, both of Novus Scientific
www.novusscientific.com


'/>"/>
SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
2. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
4. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
5. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
6. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
7. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
8. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
9. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
10. Matrixx Initiatives, Inc. Announces End of Go-Shop Period
11. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Omnicell, Inc. (Nasdaq: OMCL ) a leading ... they will present at the UBS 21st Annual Global Healthcare ... Omnicell Speakers: Rob Seim, vice president ... DevelopmentDate: Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: ...
... LLC , ( www.curemark.com ), a drug research and ... recently hosted New York Senator Kirsten Gillibrand as she ... creation, locally and nationally.  Speaking at Curemark, which is ... proposal to expand, simplify and make permanent the Research ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Curemark Hosts New York Senator Kirsten Gillibrand 2Curemark Hosts New York Senator Kirsten Gillibrand 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... suffer an adverse medical event arising from the use or ... system than other emergency department (ED) patients, say physicians and ... the first to examine the health outcomes and cost of ... drug events, is published today in the Annals of ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... of plague will probably remain a scourge of centuries past, ... In fact, according to a just-released government report, a American ... case of plague from a laboratory-acquired infection since 1959 and ...
... in one large U.S. healthcare network since publication of ... according to a study published online February 24 in ... In 2008, the U.S. Preventive Services Task Force ... The following year, investigators from two large screening trials ...
... experiences and substance abuse has been discovered by researchers ... correlation is especially prevalent among gays, lesbians and bisexuals ... professor and interim head of health systems science in ... of the study, published in the journal Addiction ...
... , THURSDAY, Feb. 24 (HealthDay News) -- Fewer ... antigen (PSA) screening for prostate cancer since the release of ... a few years ago, say researchers. This study examined ... the decline in PSA screening was three percent among men ...
... been associated with a reduced risk of breast cancer, but ... gives birth, the higher her risk of "triple-negative" breast cancer, ... Conversely, women who never give birth have a 40 percent ... prognosis than other types of breast cancer and doesn,t respond ...
Cached Medicine News:Health News:Adverse drug events costly to health care system: Vancouver Coastal Health-UBC research 2Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Strong link found between victimization, substance abuse 2Health News:PSA Screening for Prostate Cancer Dips in Large U.S. Health Network 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3
... The Burdick EK-10 single-channel,electrocardiograph ... touch membrane keypad. It ... make a quick and,accurate ... ergonomically,designed with a built ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: